Cannabis-Induced Psychosis
Psychotic symptoms (hallucinations, delusions, disorganized thinking) precipitated by cannabis use. Risk is higher with high-potency THC products and in genetically predisposed individuals.
In Depth
Acute cannabis-induced psychosis is dose-dependent and typically resolves within hours to days of cessation. Chronic heavy use, particularly of high-potency products (>15% THC), is associated with increased risk of persistent psychotic disorders including schizophrenia. The risk is substantially higher in individuals with a family history of psychosis or with certain genetic variants (e.g., COMT Val158Met). CBD may counteract THC-induced psychosis — studies show CBD reduces psychotic symptoms and attenuates THC-induced psychotic-like effects.
Related Terms
More in Clinical
Dravet Syndrome
A severe, treatment-resistant form of childhood epilepsy characterized by prolonged seizures, often triggered by fever, beginning in the first year of life.
Lennox-Gastaut Syndrome (LGS)
A severe form of childhood-onset epilepsy characterized by multiple seizure types, slow spike-wave EEG pattern, and cognitive impairment.
Epidiolex
The FDA-approved pharmaceutical formulation of purified cannabidiol (CBD), manufactured by GW Pharmaceuticals (now Jazz Pharmaceuticals). Approved in 2018 for Dravet syndrome and Lennox-Gastaut syndrome.
Dronabinol (Marinol)
A synthetic form of THC (Δ9-tetrahydrocannabinol) approved by the FDA for chemotherapy-induced nausea/vomiting and AIDS-related anorexia.
Nabilone (Cesamet)
A synthetic cannabinoid analogue of THC approved for chemotherapy-induced nausea and vomiting. More potent than dronabinol.